Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe

Show full item record



Permalink

http://hdl.handle.net/10138/303676

Citation

Wickberg , A , Liljegren , G , Killander , F , Lindman , H , Bjöhle , J , Carlberg , M , Blomqvist , C , Ahlgren , J & Villman , K 2018 , ' Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe ' , European Journal of Surgical Oncology , vol. 44 , no. 7 , pp. 951-956 . https://doi.org/10.1016/j.ejso.2018.04.002

Title: Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe
Author: Wickberg, Asa; Liljegren, Goran; Killander, Fredrika; Lindman, Henrik; Bjöhle, Judith; Carlberg, Michael; Blomqvist, Carl; Ahlgren, Johan; Villman, Kenneth
Contributor: University of Helsinki, Department of Oncology
Date: 2018-07
Language: eng
Number of pages: 6
Belongs to series: European Journal of Surgical Oncology
ISSN: 0748-7983
URI: http://hdl.handle.net/10138/303676
Abstract: Purpose: The aim of this study was to verify if radiotherapy (RT) safely can be omitted in older women treated for estrogen-receptor positive early breast cancer with breast-conserving surgery (BCS) and endocrine therapy (ET). Patients and Methods: Eligibility criteria were: consecutive patients with age >= 65 years, BCS + sentinel node biopsy, clear margins, unifocal T1N0M0 breast cancer tumor, Elston-Ellis histological grade 1 or 2 and estrogen receptor-positive tumor. After informed consent, adjuvant ET for 5 years was prescribed. Primary endpoint was ipsilateral breast tumor recurrence (IBTR). Secondary endpoints were contralateral breast cancer and overall survival. Results: Between 2006 and 2012, 603 women were included from 14 Swedish centers. Median age was 71.1 years (range 65-90). After a median follow-up of 68 months 16 IBTR (cumulative incidence at five-year follow-up; 1.2%, 95% CI, 0.6% to 2.5%), 6 regional recurrences (one combined with IBTR), 2 distant recurrences (both without IBTR or regional recurrence) and 13 contralateral breast cancers were observed. There were 48 deaths. One death (2.1%) was due to breast cancer and 13 (27.1%) were due to other cancers (2 endometrial cancers). Five-year overall survival was 93.0% (95% CI, 90.5% to 94.9%). Conclusion: BCS and ET without RT seem to be a safe treatment option in women >= 65 years with early breast cancer and favorable histopathology. The risk of IBTR is comparable to the risk of contralateral breast cancer. Moreover, concurrent morbidity dominates over breast cancer as leading cause of death in this cohort with low-risk breast tumors. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Subject: Breast-conserving surgery
Endocrine therapy
Postoperative radiotherapy
RANDOMIZED CLINICAL-TRIAL
PATIENT-LEVEL METAANALYSIS
LUMPECTOMY PLUS TAMOXIFEN
ISCHEMIC-HEART-DISEASE
TERM-FOLLOW-UP
POSTOPERATIVE RADIOTHERAPY
SECTOR RESECTION
IRRADIATION
OLDER
AGE
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0748798318310072_main.pdf 511.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record